Antigenic sites in SARS-CoV-2 spike RBD show molecular similarity with pathogenic antigenic determinants and harbors peptides for vaccine development
Immunobiology. 2021 Jul 13;226(5):152091. doi: 10.1016/j.imbio.2021.152091. Online ahead of print.ABSTRACTThe spike protein of coronavirus is key target for drug development and other pharmacological interventions. In current study, we performed an integrative approach to predict antigenic sites in SARS-CoV-2 spike receptor binding domain and found nine potential antigenic sites. The predicted antigenic sites were then assessed for possible molecular similarity with other known antigens in different organisms. Out of nine sites, seven sites showed molecular similarity with 54 antigenic determinants found in twelve pathogenic bacterial species (Mycobacterium tuberculosis, Mycobacterium leprae, Bacillus anthracis, Borrelia burgdorferi, Clostridium perfringens, Clostridium tetani, Helicobacter Pylori, Listeria monocytogenes, Staphylococcus aureus, Streptococcus pyogenes, Vibrio cholera and Yersinia pestis), two malarial parasites (Plasmodium falciparum and Plasmodium knowlesi) and influenza virus A. Most of the bacterial antigens that displayed molecular similarity with antigenic sites in SARS-CoV-2 RBD (receptor binding domain) were toxins and virulent factors. Antigens from Mycobacterium that showed similarity were mainly involved in modulating host cell immune response and ensuring persistence and survival of pathogen in host cells. Presence of a large number of antigenic determinants, similar to those in highly pathogenic microorganisms, not merely accounts for complex etiol...
ConclusionThe recommended IV dose of 10 mg/kg q8h, not exceeding 400 mg q8h, would achieve AUC0-24 h to successfully treat bacteria with MICs ≤ 0.25 (e.g. Salmonella, Escherichia coli, Proteus, Haemophilus, Enterobacter, and Klebsiella). A dose increase to 600 mg q8h in children > 40 kg and to 15 mg/kg q8h (max 400 mg q8h, max 600 mg q8h if augmented renal clearance, i.e., eGFR > 200 mL/min/1.73 m2) in children
This study aimed to understand the extent to which cannabis-related risk perception and COVID-19-related health worries were associated with the reported reduction in sharing cannabis smoking products to mitigate the risk of the coronavirus transmission or infection. This association was tested in two different periods in terms of toughness of national lockdown policy imposed in the first months of the pandemic in Israel. The study population included adult recreational cannabis users who completed one of the two online cross-sectional surveys dedicated to COVID-19 and the cannabis use situation in Israel in the first h...
“Last March, I was working in a small primary care practice on the west side of Denver. COVID-19 came to town. On Thursday, March 12, we were told the schools would be closing. On Friday, we were told that clinic staff had to wear masks — and the clinic had to start testing patients forRead more …I was thinking about retiring, and COVID-19 gave me a push [PODCAST] originally appeared inKevinMD.com.
OHSU's vaccination results are in line with other major Portland health systems.
More News: Allergy & Immunology | Anthrax | Anthrax Vaccine | Borrelia | Cholera | Clostridium Perfringens | Coronavirus | COVID-19 | Helicobacter Pylori | Influenza | Influenza Vaccine | Leprosy | Listeria | Lyme Disease | Malaria | Malaria Vaccine | Parasitic Diseases | Parasitology | SARS | Staphylococcus Aureus | Study | Tuberculosis | Vaccines | Yersinia